Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine is a synthetic small molecule belonging to the imidazo[1,5-a]pyrazine class of aromatic heteropolycyclic compounds. It has the molecular formula C20H18N4 and a molecular weight of approximately 314.38 g/mol. The compound is characterized by an imidazopyrazine core substituted with phenyl and dimethylphenyl groups. According to available data from DrugBank and structural databases (including PDB ligand KSL), this molecule acts as an inhibitor of tyrosine-protein kinase Lck (Lymphocyte-specific protein tyrosine kinase), with reported in vitro activity (IC50 ~20 nM). There are no known approved clinical uses or indications for this compound; it appears to be primarily used as a research tool in biochemical studies targeting Lck or related kinases[2][7][10].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine.